HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Locoregional therapy with polyethylene-glycol-modified interleukin-2 of an intradermally growing hepatocellular carcinoma in the guinea pig induces T-cell-mediated antitumor activity.

Abstract
Therapy with repeated intratumoral and perilymphatic administration of relatively low doses of polyethylene-glycol(PEG)-modified interleukin-2 (IL-2) in the syngeneic guinea pig line 10 (L10) hepatocarcinoma results in significant local tumor growth inhibition and a delay in development of regional lymph node metastases of more than 3 weeks when compared to controls. Occasionally animals are cured of tumor. The mechanism of this antitumor activity was studied. The antitumor activity of locoregionally administered PEG-IL-2 was abrogated by pretreatment with polyclonal anti-thymocyte serum, indicating that the observed tumor growth inhibition was a T-cell-mediated phenomenon. Besides the locoregional tumor growth inhibition, a systemic effect was recorded as the growth of a second tumor cell inoculum at the contralateral side was inhibited as well. Furthermore, those animals cured after PEG-IL-2 therapy developed specific immunity against the L10 tumor and this immunity could be transferred to naive animals by spleen cells. Immunohistological observations of the tumor site revealed a slight increase of helper and cytotoxic T cell subpopulations after PEG-IL-2 therapy. More pronounced, however, was the rise in number of eosinophilic granulocytes present in the stroma surrounding the tumor cells. Involvement of cytotoxic cells in the antitumor effects of PEG-IL-2 could not be demonstrated: regional lymph node cells and spleen cells obtained immediately after therapy (day 15) or on day 21 showed no cytotoxic activity in vitro against L10, K562, Daudi and line 1 (L1) target cells. In conclusion, locoregional therapy with PEG-IL-2 induced a a systemic T-cell-mediated antitumor response. As no cytotoxic T cell activity was measured, however, the underlying mechanism is most likely a T-helper response. Eosinophils at the tumor site may be tumoricidal but further experiments must reveal the role of these cells in the PEG-IL-2-induced tumor regression.
AuthorsL T Balemans, V Mattijssen, P A Steerenberg, B E Van Driel, P H De Mulder, W Den Otter
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 37 Issue 1 Pg. 7-14 (Jul 1993) ISSN: 0340-7004 [Print] Germany
PMID8513455 (Publication Type: Journal Article)
Chemical References
  • Antigens, Neoplasm
  • Cell Adhesion Molecules, Neuronal
  • Interleukin-2
  • Leukocyte L1 Antigen Complex
  • interleukin-2, polyethylene glycol-modified
  • Polyethylene Glycols
Topics
  • Animals
  • Antigens, Neoplasm (immunology)
  • Cell Adhesion Molecules, Neuronal (immunology)
  • Cytotoxicity Tests, Immunologic
  • Female
  • Fibrosis (drug therapy)
  • Granulocytes (drug effects)
  • Guinea Pigs
  • Immunity, Cellular
  • Immunohistochemistry
  • Immunotherapy, Adoptive
  • Injections, Intralesional
  • Injections, Intralymphatic
  • Interleukin-2 (administration & dosage, analogs & derivatives, pharmacology, therapeutic use)
  • Leukocyte L1 Antigen Complex
  • Liver Neoplasms, Experimental (immunology, pathology, therapy)
  • Lymphatic Metastasis (immunology, prevention & control)
  • Male
  • Neoplasm Transplantation
  • Polyethylene Glycols
  • Remission Induction
  • Splenic Neoplasms (immunology, prevention & control, secondary)
  • T-Lymphocyte Subsets (drug effects, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: